NanoHive Medical received FDA 510(k) clearance to market its 22mm length Hive™ PL Interbody System. The 22mm length implants are a line extension to the current Hive PLIF interbody devices and feature a 9mm width and variety of height and lordotic options to accommodate patient anatomy.
Additionally, the regulatory clearance includes updated description of the microscopic roughened surfaces with micro and nano-scale features found on all surfaces of the Hive Soft Titanium® interbodies, including the superior, inferior and peripheral surfaces, as well as each member of the internal cell structure.
The company’s Hive Lumbar Interbody System, with a microscopic roughened surface and micro and nano-scale features, is indicated for use in skeletally mature patients with Degenerative Disc Disease at one or two contiguous levels from L2-S1. The system must be used with supplemental fixation, with autograft or allograft bone.
NanoHive Medical received FDA 510(k) clearance to market its 22mm length Hive™ PL Interbody System. The 22mm length implants are a line extension to the current Hive PLIF interbody devices and feature a 9mm width and variety of height and lordotic options to accommodate patient anatomy.
Additionally, the regulatory clearance includes updated...
NanoHive Medical received FDA 510(k) clearance to market its 22mm length Hive™ PL Interbody System. The 22mm length implants are a line extension to the current Hive PLIF interbody devices and feature a 9mm width and variety of height and lordotic options to accommodate patient anatomy.
Additionally, the regulatory clearance includes updated description of the microscopic roughened surfaces with micro and nano-scale features found on all surfaces of the Hive Soft Titanium® interbodies, including the superior, inferior and peripheral surfaces, as well as each member of the internal cell structure.
The company’s Hive Lumbar Interbody System, with a microscopic roughened surface and micro and nano-scale features, is indicated for use in skeletally mature patients with Degenerative Disc Disease at one or two contiguous levels from L2-S1. The system must be used with supplemental fixation, with autograft or allograft bone.
Copy to clipboard 
